Evidence map›Paper›PMID 31833113›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2020

Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer.

Toshikazu Takeda, Amy L Tin, Renato B Corradi, Ricardo Alvim, Takeshi Hashimoto, Yujiro Ito, Daniel P Nguyen, Maha Mamoor, Nicola L Robertson, Hebert A Vargas and 7 more

Open access · greenAbstract read
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Toshikazu TakedaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Amy L TinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Renato B CorradiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Ricardo AlvimUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Takeshi HashimotoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Yujiro ItoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Daniel P NguyenUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Maha MamoorUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Nicola L RobertsonDepartments of, Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Hebert A VargasDepartments of, Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Nicole E BenfanteDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Daniel D SjobergDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
James A EasthamUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Peter T ScardinoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Samson W FineDepartment of, Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Karim A TouijerUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Memorial Sloan Kettering Cancer Center · USKeio University · JPHospital Neuchâtel · CH

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748Sidney Kimmel Center for Prostate and Urologic Cancers
6 · The paper itself

Abstract

objectiveTo examine a set of proposed eligibility factors for hemi-ablative focal therapy in prostate cancer and to determine the likelihood of residual extensive disease.

methodsWe retrospectively analyzed data from 98 patients with unilateral prostate cancer on biopsy with detailed tumor maps from whole-mount slides and preoperative magnetic resonance imaging data. These patients met the focal therapy consensus meeting inclusion criteria (prostate-specific antigen <15 ng/mL, clinical stage T1c-T2a and Gleason score 3 + 3 or 3 + 4 on needle biopsy), and underwent radical prostatectomy between 2000 and 2014. Extensive disease was defined as having Gleason pattern 4/5 in bilateral lobes, any extraprostatic extension, seminal vesicle invasion or lymph node invasion. Both lobes of the prostate were scored on magnetic resonance imaging. Preoperative characteristics including biopsy and magnetic resonance imaging data were used to predict extensive disease.

resultsAmong our cohort of 98 patients, 40% (95% CI 30-50%) had extensive disease. A total of 33% (95% CI 24-43%) had Gleason pattern 4/5 in both lobes with a median Gleason pattern 4/5 tumor volume in the biopsy negative lobe of 0.06 cm

conclusionsAn important number of patients meeting the focal therapy consensus meeting inclusion criteria can present extensive disease. Further studies using targeted biopsies might provide more accurate information about the selection of focal therapy candidates.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsHumansMaleNeoplasm GradingNeoplasm StagingProstatectomyRetrospective StudiesProstate-Specific Antigenablation techniquesbiopsymagnetic resonance imagingpathologyprostatic neoplasms

Identifiers

PMID31833113
PMCPMC8407533
OpenAlexW2995511442

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.